Advanced searches left 3/3

Cell Communication And Signaling - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 10 December 2022

* If you want to update the article please login/register

Innate Immunity Signal Transduction in Human Leukocytes

We want to know how white blood cells respond to various stimuli in the test tube, to see how they detect the signals in the body and what chemicals they produce. We want to investigate the response of the whole blood to potential disease-associated conditions in the blood plasma that may lead to the stimulation of white blood cells to increase white blood cells. Adult, nonpregnant, healthy volunteers will have 320 ml of whole blood collected by venipuncture in a controlled environment no more often than every eight weeks than once every 8 weeks. The LPS signal transduction of the LPS signal in human leukocytes will be defined by lipid raft membrane microdomains as part of the research. LPS signaling has been shown to be sensitive to raft cholesterol content, presumably because the specific range of proteins in rafts is sensitive to raft cholesterol content. While LPS has been marketed to modulate the activity of proteins that control raft cholesterol content, no work has been done to clarify: one the mechanisms responsible for LPS-induced intracellular cholesterol redistribution, and, more importantly, 2 whether innate immunity signaling is dependent on inter-subject variations in raft cholesterol content. Dr. Menendez is one of the world leaders in the research of the tumor suppressor gene p53. Dr. Menendez's leukocytes will be isolated from whole blood in a different fashion from whole blood.

Source link: https://clinicaltrials.gov/ct2/show/NCT00397280


Brain Dopaminergic Signaling in Opioid Use Disorders (OUD)

Objectives: Primary aim is to determine whether the balance between dopamine D1 and D2 receptors signaling in striatum is disrupted in participants with an opioid use disorder who are on opioid agonist therapy related to OUD participants treated with the opioid antagonist drug naltrexone and OUD participants who are not being treated with opioids is restored and not being treated with medications. After the MP administration's decision to determine striatal DA release, participants will undergo three scans using positron emission tomography: one with [11C]NNC-112 to determine baseline D1R, another with [11C]raclopride after placebo to assess baseline D2R, and the other with [11C]raclopride after placebo testing baseline D2R. Correlations between striatal D1R to D2R and striatal DA release; fMRI implementation in rewards and control networks; and locomotor activity;.

Source link: https://clinicaltrials.gov/ct2/show/NCT03190954


The MET Signaling System, Autism and Gastrointestinal Dysfunction

The Questionnaire on Pediatric Gastrointestinal Symptoms -Rome III is administered to each child, and a board-certified pediatric gastroenterologist examines the child. If able to be tolerated by the child, the Autism Treatment Network developed its questionnaire; among the many possible problems with ASD include reflux/dyspepsia, hemorrhoids, fissures, and other possible symptoms such as reflux/dyspepsia, vomiting, headaches, increase or decrease in appetite; and, 4 medicine and diet changes were included. 1 social sensitivity questionnaire; 3 Child Behavior Checklist; 4 Aberrant Behavior Checklist; 5 Pearson Short Sensory Assessment; 8 Pearson Short Sens (Revised) At each visit, a clinical psychologist will administer the following instruments/questionnaires; 3 Kaufman Brief Intelligence Test; 2 Productivity Test; 3 Child Behavior Checklist; 3 Aberrant Behavior Checklist; 3 Child Behavior Checklist; 6 Remarkable Behavior Inventory; 5 Pearson Short Sensory Profile; 3 Overall Behavioral Assessment; 6 Reset Subject urine is collected and stored at each visit until an assay for the oxidative stress marker F2-isoprostane is determined.

Source link: https://clinicaltrials.gov/ct2/show/NCT02442115


Manipulating Ghrelin Signaling Via GOAT Inhibition in Alcohol Use Disorder

According to preliminary reports, acyl-ghrelin rises alcohol intake and reduces decreases in acyl-ghrelin and GHS-R1a functions reduces alcohol use. Moreover, new human studies have shown a positive relationship between endogenous ghrelin levels and alcohol intake and consumption. During alcohol consumption, rise alcohol intake during alcoholic intake, intravenous acyl-ghrelin treatment, and placebo 1 increased alcohol intake during alcohol intake and disposal, as well as reduced latency to first injection of alcohol and 3 increased brain stimulation in the amygdala in anticipation of alcohol reward. This preclinical and human study show that manipulating the ghrelin signal may be a novel and potentially cost-effective drug therapy strategy to treat people with alcohol use disorder. After the discovery of GHS-R1a and acyl-ghrelin, a new step was taken in finding ghrelin O-acyltransferase GOAT, the enzyme that catalyzes the conversion of des-acyl-ghrelin DAG to acyl-ghrelin DAG by octanoylation by octanoylation. Therefore, GOAT is a promising tool for manipulating the ghrelin system by altering the peripheral acyl-to-total ratio in which total ghrelin ratio = acyl-ghrelin + DAG. The GLWL-01 is an old GOAT inhibitor for which GLWL Research Inc. has recently and successfully completed a first-in-human safety clinical trial. Stage II will be held after a minimum two-day wash-out window, during which the counterbalanced study drug will be administered for a minimum of four days. Using a virtual buffet experimental technique, the primary secondary goal will be the effects of GLWL-01 on food choices.

Source link: https://clinicaltrials.gov/ct2/show/NCT03896516


[11C]-(R)-Rolipram to Measure cAMP Signaling Before and After Ketamine

This research will determine if ketamine infusion modifies human brain's cAMP system to determine if ketamine mediates its antidepressant effects in part due to modulation of cAMP signaling. Objectives: Primary Objective: Determine if ketamine infusions in depression result in rises in cAMP signaling as measured by [11C]-rolipram binding, as shown by [11C]-rolipram binding.

Source link: https://clinicaltrials.gov/ct2/show/NCT05522673


Interrogation of Exosome-mediated Intercellular Signaling in Patients With Pancreatic Cancer

Patients with pancreatic cancer's blood and tissue will be compared to blood and tissue from patients with noncancerous pancreatic disease. The investigators will then investigate whether exosome activity has a relationship to disease recurrence and patient outcomes.

Source link: https://clinicaltrials.gov/ct2/show/NCT02393703


Assessing Physical Function Following Androgen Receptor Signaling Inhibitor Treatment for Metastatic Prostate Cancer

The aim of this pilot trial was to obtain objective measurements of physical activity in men with metastatic prostate cancer initiating ARSI treatment at baseline, 12, and 24 weeks later. To determine the true consequences, accurate estimates of declines from ARSI initiation are required with more men requiring ARSI therapy for metastatic castrate resistant prostate cancer as well as being an inexpensive alternative earlier in metastatic castrate sensitive prostate cancer. Using novel findings in mPC-like muscular power tests will help reveal future more useful findings and findings to intervene on.

Source link: https://clinicaltrials.gov/ct2/show/NCT05612880


Gauging Active Modalities of Error Detection and Signaling Obtained by Neural Interfaces in the Cathlab: The GAME-ON Study

In all consecutive procedures at Ferrara University Hospital, the investigators will prospectively record and analyze Electroencephalogram results from 5 interventional cardiologists and 2 fellows in training. Given the heterogeneity of the working shifts' organization in terms of procedures' number and type, as well as their distance in time, it is then possible to assume that the same operator's psycho-physical condition differs between two different acquisition days, it is then possible to infer that the same operator's psycho-physical status diverges between two different acquisition days. For a total amount of 4 minutes, Alpha Attenuation Protocols, a sensitive test to measure sleepiness that involves measuring alpha power during a 2 cycle of eye opening/closing protocol, will be obtained. Investigators will also test several validated psychometric questionnaires: the Karolinska Sleepiness Scale, Sleep Quality Scale, and Profile of Mood States-Fatigue subscale.

Source link: https://clinicaltrials.gov/ct2/show/NCT05041218


The Effects of Dupilumab on Asthma Outcomes and IL-13Rα2 Signaling in Airway Epithelial Cells in Allergic Asthma With Comorbid BMI ≥ 30

In nasal airway epithelial cells isolated from patients with allergic vs. non-allergic asthma and comorbid obesity, determine the effect of dupilumab on gene expression and signaling activity of IL-4Ra, IL-13Ra1, and IL-13Ra2 in nasal airway epithelial cells isolated from patients with allergic vs. comorbid obesity in patients with allergic vs. non-allergic asthma and comorbid obesity Study Design: The aim is to enroll 16 adults with allergic asthma and obesity, as well as 16 adults with non-allergic asthma and obesity. According to allergies, subjects in each group will have their first screening visit to determine the subject groups. As these measurements have identified patient versus asthma and obesity in previous studies, asthma will be defined as the presence of a positive skin prick test, absolute eosinophil count > 150/uL, and serum IgE > 100 IU/ml. At V0, skin allergy testing and blood sampling will be conducted. The effect of dupilumab on transcriptomic and proteomic expression profiles, as well as fold change of IL-13Ra2 signaling, will be compared between obese allergic and obese non-allergic asthma patients. Multiple hypothesis testing will be used to adjust for multiple hypothesis testing in any of the studies conducted, according to the false discovery rate. In cultured human airway fibroblasts for 6 subjects in a lean asthma group and 7 subjects in an obese asthma group, a Baseline fold change of IL-13RA2 expression was determined. With a two-sided two-sample unequal variance t-test, a group sample size of 8 people in each group has 86. 2% power to reject the null hypothesis of equal means with a significance level of 0. 05.

Source link: https://clinicaltrials.gov/ct2/show/NCT05478824


A Phase 2 Study of Neratinib in Patients With Metastatic Castration Resistant Prostate Cancer and Increased Human Epithelial Growth Factor Receptor 2 (HER2) Signaling

Investigators are testing neratinib in prostate cancer that has widened and is no longer responding to hormonal therapy in this research article. This research involves testing tumors for increased HER2 signaling, and treating those who do have elevated HER2 signaling with a targeted therapy. The investigation found that screening for eligibility and study management was performed as part of the study's findings and follow-up visits. A series of Phase II clinical trials investigate the safety and effectiveness of an investigational drug to see if the drug is safe and effective in treating a particular disease.

Source link: https://clinicaltrials.gov/ct2/show/NCT04781374

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions